Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Method of Gene Therapy Alters Immune Cells for Treatment of Advanced Melanoma

Published: Friday, September 01, 2006
Last Updated: Friday, September 01, 2006
Bookmark and Share
Technique may also apply to other common cancers.

A team of researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, has demonstrated sustained regression of advanced melanoma in a study of 17 patients by genetically engineering patients' own white blood cells to recognize and attack cancer cells. The study appears in the online edition of the journal "Science" on August 31, 2006.

"These results represent the first time gene therapy has been used successfully to treat cancer," said NIH Director Elias A. Zerhouni, M.D.

"Moreover, we hope it will be applicable not only to melanoma, but also for a broad range of common cancers, such as breast and lung cancer."

Autologous lymphocytes - a person's own white blood cells - have previously been used to treat metastatic melanoma.

In a process called adoptive cell transfer, lymphocytes are first removed from patients with advanced melanoma.

Next, the aggressive tumor-killing cells are isolated, multiplied in the lab, and then reintroduced to patients who have been depleted of all remaining lymphocytes.

While reasonably successful, this method can only be used for melanoma patients and only for those who already have a population of specialized lymphocytes that recognize tumors as abnormal cells.

Thus, NCI researchers, led by Steven A. Rosenberg, M.D., Ph.D., sought an effective way to convert normal lymphocytes in the lab into cancer-fighting cells.

To do this, they drew a small sample of blood that contained normal lymphocytes from individual patients and infected the cells with a retrovirus in the laboratory.

The retrovirus acts like a carrier pigeon to deliver genes that encode specific proteins, called T cell receptors (TCRs), into cells.

When the genes are turned on, TCRs are made and these receptor proteins decorate the outer surface of the lymphocytes.

The TCRs act as homing devices in that they recognize and bind to certain molecules found on the surface of tumor cells. The TCRs then activate the lymphocytes to destroy the cancer cells.

In this study, newly engineered lymphocytes were infused into 17 patients with advanced metastatic melanoma.

There were three groups of patients in this study. The first group consisted of three patients who showed no delay in the progression of their disease.

As the study evolved, the researchers improved the treatment of lymphocytes in the lab so that the cells could be administered in their most active growth phase. In the remaining two groups, patients received the improved treatments.

Two patients experienced cancer regression, had sustained high levels of genetically altered lymphocytes, and remained disease-free over one year.

One month after receiving gene therapy, all patients in the last two groups still had 9 percent to 56 percent of their TCR-expressing lymphocytes. There were no toxic side effects attributed to the genetically modified cells in any patient.

Approaches to increase the function of the engineered TCRs - including the development of TCRs that can bind to tumor cells more tightly - and to further optimize delivery methods using retroviruses are under investigation.

In addition, the researchers believe it may be beneficial to further modify lymphocytes by inserting molecules that assist in directing lymphocytes to cancerous tissues.

Clinical trials are being conducted to enhance treatment effectiveness using total body radiation therapy to deplete a patient's supply of non-altered lymphocytes before replacing them with purely engineered cells.

The researchers also have isolated TCRs that recognize common cancers other than melanoma.

"We are currently treating advanced melanoma patients using adoptive transfer of genetically altered lymphocytes, and we have now expressed other lymphocyte receptors that recognize breast, lung, and other cancers," said Rosenberg.

"These very exciting successes in treating advanced melanoma bring hope that this type of gene therapy, altering lymphocytes, could be used in many types of common cancers and could be achievable in the near future," said NCI Director John E. Niederhuber, M.D.

"He is one of the leaders we all look to for moving us forward," Niederhuber said.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

2011 Biospecimen Research Network (BRN) Symposium
The National Cancer Institute's (NCI) Biospecimen Research Network Symposium, "Advancing Cancer Research Through Biospecimen Science," will be held March 28-29, 2011, at the Bethesda North Marriott Hotel & Conference Center in Bethesda, MD
Friday, January 07, 2011
Scientists Identify Markers on Human Breast Cancer Cells Linked to Development of a Form of Breast Cancer
The scientists named these human cells with tumor-forming ability in mice, xenograft-initiating cells, or XIC.
Friday, May 21, 2010
Drug for Multiple Myeloma Demonstrated to Extend Disease-Free Survival
Patients receiving lenalidomide following a blood stem cell transplant had their cancer kept in check longer than placebo receiving patients.
Thursday, December 24, 2009
Cancer Immunotherapy Can Use Small Numbers of Stem-Like Immune Cells to Destroy Large Tumors in Mice
New approach to stimulating immune cells enhances their anticancer activity, resulting in a powerful anti-tumor response in mice.
Friday, June 26, 2009
Mouse Studies Show Gene Therapy Method Holds Promise in Targeting Tumor Blood Vessels for Destruction
Cancer researchers develop method for delivering a therapeutic gene specifically to the blood vessels of tumors in mice.
Thursday, December 18, 2008
Researchers Develop a Method to Evaluate Variations Identified in Breast Cancer Susceptibility Genes
The researchers believe that the new test could become a useful and viable tool for genetic counselors, and may have implications beyond cancer.
Tuesday, July 08, 2008
Scientific News
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
New Material Forges the Way for 'Stem Cell Factories'
Researchers have discovered the first fully synthetic substrate with potential to grow billions of stem cells. The researchcould forge the way for the creation of 'stem cell factories' - the mass production of human embryonic (pluripotent) stem cells.
Liver Regrown from Stem Cells
Scientists have repaired a damaged liver in a mouse by transplanting stem cells grown in the laboratory.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
'Google Maps' for the Body
Scientists have revealed research that uses previously top-secret technology to zoom through the human body down to the level of a single cell that could be a game-changer for medicine.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Stem Cells Rescue Patients from Mitochondrial Disease
A study led by OHSU researchers has revealed a critical first step in developing a new gene and stem cell regenerative technique for treating patients with mitochondrial disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!